Head-to-head evidence
Baxdrostat vs Lorundrostat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Aldosterone synthase (CYP11B2) · full Hypertension pipeline
Baxdrostat · Baxfendy
Marketed by AstraZeneca
NCT06034743 · Phase 3 · completed
The trial randomized 794 participants to baxdrostat or matching placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Both prespecified primary blood-pressure endpoints were met at Week 12: the reduction in seated systolic blood pressure was greater with 2 mg and 1 mg baxdrostat than with placebo, with p<0.0001 for each comparison.
Next expected readout: December 2026 · NCT07222917 (registry estimate)
Lorundrostat
Developed by Mineralys Therapeutics
NCT05432167 · Phase 2 · completed
In this 195-participant randomized, double-blind, placebo-controlled trial, the primary clinical endpoint was met: pooled CIN-107 reduced seated systolic blood pressure by 15.22 mmHg versus 7.15 mmHg with placebo, a between-group difference of 8.08 mmHg (p=0.003). The trial had a substantial sample size and the primary comparison was statistically significant in the favorable direction.
Chronic Kidney Disease
Shared mechanism: Aldosterone synthase (CYP11B2) · full Chronic Kidney Disease pipeline
Baxdrostat · Baxfendy
Marketed by AstraZeneca
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07222917 (registry estimate)
Lorundrostat
Developed by Mineralys Therapeutics
NCT05432167 · Phase 2 · completed
In this 195-participant randomized, double-blind, placebo-controlled trial, the primary clinical endpoint was met: pooled CIN-107 reduced seated systolic blood pressure by 15.22 mmHg versus 7.15 mmHg with placebo, a between-group difference of 8.08 mmHg (p=0.003). The trial had a substantial sample size and the primary comparison was statistically significant in the favorable direction.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Baxdrostat's landscape · Lorundrostat's landscape